| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Simon Erridge, Carl Holvey, Ross Coomber, Jonathan Hoare, Shaheen Khan, Michael Platt, James Rucker, Mark Weatherall, Sushil Beri, Mikael Sodergre. Clinical Outcome Data of Children Treated with Cannabis Based Medicinal Products for Treatment Resistant Epilepsy - Analysis from the UK Medical Cannabis Registry. Neuropediatrics. 2022-12-20. PMID:36539215. |
clinical outcome data of children treated with cannabis based medicinal products for treatment resistant epilepsy - analysis from the uk medical cannabis registry. |
2022-12-20 |
2023-08-14 |
Not clear |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B. vol 138. 2022-12-15. PMID:36473301. |
analysis of youtube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. |
2022-12-15 |
2023-08-14 |
Not clear |
| Hakan Silek, Ozgur Bilgin Topcuogl. Analysis of YouTube videos as a source of information for reliability and effectiveness of cannabidiol oil in treatment of epilepsy. Epilepsy & behavior : E&B. vol 138. 2022-12-15. PMID:36473301. |
cannabidiol (cbd) oil has been used for the treatment of refractory epilepsy for a long time. |
2022-12-15 |
2023-08-14 |
Not clear |
| Lindsay F Smegal, Pooja Vedmurthy, Matthew Ryan, Melissa Eagen, Nicole Whiston Andrejow, Kristie Sweeney, Teressa Garcia Reidy, SangEun Yeom, Doris D Lin, Stacy J Suskauer, Luther G Kalb, Jay A Salpekar, T Andrew Zabel, Anne M Com. Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Symptoms in Sturge-Weber Syndrome. Pediatric neurology. vol 139. 2022-12-12. PMID:36508880. |
a prior drug trial of cannabidiol for treatment-resistant epilepsy in patients with sturge-weber syndrome (sws), a rare neurovascular condition, implicated improvements in neurological, quality of life (qol), neuropsychologic, psychiatric, and motor outcomes. |
2022-12-12 |
2023-08-14 |
Not clear |
| Victoria Golub, Sreevidhya Ramakrishnan, Doodipala Samba Redd. Isobolographic analysis of adjunct Antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. Experimental neurology. 2022-12-09. PMID:36493860. |
isobolographic analysis of adjunct antiseizure activity of the fda-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. |
2022-12-09 |
2023-08-14 |
Not clear |
| Victoria Golub, Sreevidhya Ramakrishnan, Doodipala Samba Redd. Isobolographic analysis of adjunct Antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. Experimental neurology. 2022-12-09. PMID:36493860. |
cannabidiol (cbd) has been shown to decrease seizures in pediatric epilepsies, such as dravet and lennox-gastaut syndromes; however, it has not been rigorously tested for adult seizures or in models of refractory focal epilepsy. |
2022-12-09 |
2023-08-14 |
Not clear |
| Aaron Del Pozo, Melissa Barker-Halisk. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Experimental neurology. vol 360. 2022-12-06. PMID:36471511. |
cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. |
2022-12-06 |
2023-08-14 |
Not clear |
| Aaron Del Pozo, Melissa Barker-Halisk. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Experimental neurology. vol 360. 2022-12-06. PMID:36471511. |
this commentary aims to review the historical relevance of cannabidiol's (cbd; epidiolex) approval for epilepsy in the context of other asms brought to market. |
2022-12-06 |
2023-08-14 |
Not clear |
| Aaron Del Pozo, Melissa Barker-Halisk. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Experimental neurology. vol 360. 2022-12-06. PMID:36471511. |
because of the clinical approval of cbd as a novel, cannabis plantderived asm for ds, cbd has revealed a new strategy in asm discovery to reignite 21st century therapeutic development for epilepsy. |
2022-12-06 |
2023-08-14 |
Not clear |
| John S Markowitz, Ludmila De Faria, Qingchen Zhang, Philip W Melchert, Reginald F Frye, Brandon O Klee, Yuli Qia. The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects. Medical cannabis and cannabinoids. vol 5. issue 1. 2022-12-05. PMID:36467779. |
cannabidiol (cbd) is a widely utilized nonpsychoactive cannabinoid available as an over-the-counter supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies. |
2022-12-05 |
2023-08-14 |
human |
| Antônio Silvinato, Idevaldo Floriano, Wanderley Marques Bernard. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Revista da Associacao Medica Brasileira (1992). vol 68. issue 10. 2022-11-23. PMID:36417631. |
use of cannabidiol in the treatment of epilepsy: lennox-gastaut syndrome, dravet syndrome, and tuberous sclerosis complex. |
2022-11-23 |
2023-08-14 |
Not clear |
| Vicente Villanueva, Adrián García-Ron, Patricia Smeyers, Eva Arias, Victor Soto, Juan José García-Peñas, Elena González-Alguacil, Débora Sayas, Pedro Serrano-Castro, Mercedes Garces, Kevin Hampel, Miguel Tomás, Julian Lara, María de Toledo, Ines Barceló, Angel Aledo-Serrano, Antonio Gil-Nagel, Lucas Iacampo, Mercè Falip, Rosa Ana Saiz-Diaz, Asier Gómez-Ibañez, David Sopelana, Alvaro Sanchez-Larsen, Francisco Javier López-Gonzále. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy. Epilepsy & behavior : E&B. vol 137. issue Pt A. 2022-11-03. PMID:36327646. |
outcomes from a spanish expanded access program on cannabidiol treatment in pediatric and adult patients with epilepsy. |
2022-11-03 |
2023-08-14 |
Not clear |
| Heidrun Potschka, Sofie F M Bhatti, Andrea Tipold, Stephanie McGrat. Cannabidiol in canine epilepsy. Veterinary journal (London, England : 1997). 2022-10-09. PMID:36209995. |
cannabidiol in canine epilepsy. |
2022-10-09 |
2023-08-14 |
human |
| Heidrun Potschka, Sofie F M Bhatti, Andrea Tipold, Stephanie McGrat. Cannabidiol in canine epilepsy. Veterinary journal (London, England : 1997). 2022-10-09. PMID:36209995. |
randomized controlled canine trials with large sample sizes are needed to determine the range of therapeutic plasma concentrations, develop evidence-based dosing regimens, determine the efficacy of cannabidiol in drug-refractory epilepsy, and explore potential associations between treatment effects and different etiologies, epilepsy types, and drug combinations. |
2022-10-09 |
2023-08-14 |
human |
| Ashna Talwar, Emily Estes, Rajender Aparasu, Doodipala Samba Redd. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Experimental neurology. 2022-10-07. PMID:36206805. |
clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis. |
2022-10-07 |
2023-08-14 |
Not clear |
| Doodipala Samba Redd. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. Experimental neurology. 2022-10-07. PMID:36206806. |
therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. |
2022-10-07 |
2023-08-14 |
Not clear |
| Willian Lazarini-Lopes, Carolina Campos-Rodriguez, Norberto Garcia-Cairasco, Prosper N'Gouemo, Patrick A Forcell. Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain. Pharmacological reports : PR. 2022-10-04. PMID:36195689. |
cannabidiol (cbd) has been of rapidly growing interest in the epilepsy research field due to its antiseizure properties in preclinical models and patients with pharmacoresistant epilepsy. |
2022-10-04 |
2023-08-14 |
rat |
| Ljubica Mihailova, Jana Tchekalarova, Dushko Shalabalija, Nikola Geskovski, Veronika Stoilkovska Gjorgievska, Gjoshe Stefkov, Paoleta Krasteva, Maja Simonoska Crcarevska, Marija Glavas Dodo. Lipid nano-carriers loaded with Cannabis sativa extract for epilepsy treatment - in vitro characterization and in vivo efficacy studies. Journal of pharmaceutical sciences. 2022-10-03. PMID:36189477. |
lipid nano-carriers loaded with cannabis sativa extract for epilepsy treatment - in vitro characterization and in vivo efficacy studies. |
2022-10-03 |
2023-08-14 |
Not clear |
| Ljubica Mihailova, Jana Tchekalarova, Dushko Shalabalija, Nikola Geskovski, Veronika Stoilkovska Gjorgievska, Gjoshe Stefkov, Paoleta Krasteva, Maja Simonoska Crcarevska, Marija Glavas Dodo. Lipid nano-carriers loaded with Cannabis sativa extract for epilepsy treatment - in vitro characterization and in vivo efficacy studies. Journal of pharmaceutical sciences. 2022-10-03. PMID:36189477. |
taking into consideration the latest reported beneficial anticolvusant effects of cannabidiol (cbd) and cannabiodiolic acid (cbda) for clinical applications and the advantages of lipid nano-systems as carriers for targeted brain delivery, the aim of this study was set in direction of in vitro physico-chemical and biopharmaceutical characterization and in vivo evaluation of nanoliposomes and nanostructured lipid carriers loaded with cannabis sativa extract intended for safe and efficient transport via blood-brain barrier and treatment of epilepsy. |
2022-10-03 |
2023-08-14 |
Not clear |
| Olabimpe Olafuyi, Karina Kapusta, Alexander Reed, Wojciech Kolodziejczyk, Julia Saloni, Glake A Hil. Investigation of cannabidiol's potential targets in limbic seizures. Journal of biomolecular structure & dynamics. 2022-09-21. PMID:36129109. |
in clinical and preclinical studies, various investigations have shown the advantage of specific plant-based cannabidiol (cbd) products in treating certain groups of people with limbic epilepsy who have failed to respond to conventional therapies. |
2022-09-21 |
2023-08-14 |
Not clear |